glp-1 medications side effects Part 2 of a 3-Part Series; for Weight Loss Exploring the Side Effects of

Emerging Safety Concerns Recent research has identified new safety considerations beyond traditional gastrointestinal effects

LY3298176, a novel long-actingGIP/GLP-1 coagonist, shows enhanced activity on weight loss and energy utilization whilst maintaining its efficacy for glycaemic control

After ingesting the tablets whole, wait at least half an hour before eating, drinking, or taking any other drugs

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations

Branded Saxenda sales fell to roughly $300 million in the first half of 2025 as newer GLP-1 therapies, including semaglutide and tirzepatide, gained market share

In total, 133 studies were included in the final review